JP2015535261A - ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ - Google Patents

ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ Download PDF

Info

Publication number
JP2015535261A
JP2015535261A JP2015539919A JP2015539919A JP2015535261A JP 2015535261 A JP2015535261 A JP 2015535261A JP 2015539919 A JP2015539919 A JP 2015539919A JP 2015539919 A JP2015539919 A JP 2015539919A JP 2015535261 A JP2015535261 A JP 2015535261A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
aryl
cycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535261A5 (enExample
Inventor
アンブラード，フランク
コーツ，スティーブン，ジェー．
シナジ，レイモンド，エフ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Cocrystal Pharma Inc
Original Assignee
Emory University
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, Cocrystal Pharma Inc filed Critical Emory University
Publication of JP2015535261A publication Critical patent/JP2015535261A/ja
Publication of JP2015535261A5 publication Critical patent/JP2015535261A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2015539919A 2012-10-29 2013-10-29 ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ Pending JP2015535261A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261719696P 2012-10-29 2012-10-29
US61/719,696 2012-10-29
US201361763534P 2013-02-12 2013-02-12
US61/763,534 2013-02-12
PCT/US2013/067309 WO2014070771A1 (en) 2012-10-29 2013-10-29 Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer

Publications (2)

Publication Number Publication Date
JP2015535261A true JP2015535261A (ja) 2015-12-10
JP2015535261A5 JP2015535261A5 (enExample) 2016-12-15

Family

ID=50627997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539919A Pending JP2015535261A (ja) 2012-10-29 2013-10-29 ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ

Country Status (11)

Country Link
US (1) US9809616B2 (enExample)
EP (1) EP2912050A4 (enExample)
JP (1) JP2015535261A (enExample)
KR (1) KR20150090894A (enExample)
CN (1) CN104884462A (enExample)
BR (1) BR112015009636A8 (enExample)
CA (1) CA2889717A1 (enExample)
HK (1) HK1214270A1 (enExample)
MX (1) MX2015005500A (enExample)
RU (1) RU2015119999A (enExample)
WO (1) WO2014070771A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505530A (ja) * 2017-12-07 2021-02-18 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2021523129A (ja) * 2018-05-09 2021-09-02 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. Ｈｃｖを治療するための併用療法
JP2022117326A (ja) * 2021-01-29 2022-08-10 国立大学法人東海国立大学機構 プロドラッグ化合物

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
SI2794627T1 (sl) 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PL2861611T3 (pl) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Nukleozydy uracylowe spirooksetanu
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
ES2865402T3 (es) 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
US9828409B2 (en) * 2014-03-19 2017-11-28 Minghong Zhong Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides
PE20170698A1 (es) * 2014-09-26 2017-06-05 Riboscience Llc Derivados de nucleosidos sustituidos con 4'-vinilo como inhibidores de la replicacion del arn del virus respiratorio sincitial
EP3233878B1 (en) 2014-12-15 2025-09-03 Emory University Phosphoramidates for the treatment of hepatitis b virus
CN118286245A (zh) * 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
WO2016178876A2 (en) * 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US10874683B2 (en) 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
EA201990059A1 (ru) * 2016-06-24 2019-07-31 Эмори Юниверсити Фосфорамидаты для лечения вируса гепатита b
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
US10519186B2 (en) 2017-02-01 2019-12-31 Atea Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
PT3592430T (pt) * 2017-03-10 2024-09-05 Lakewood Amedex Inc Compostos antimicrobianos, composições e suas utilizações
KR20200140865A (ko) 2018-04-10 2020-12-16 아테아 파마슈티컬즈, 인크. 간경변증을 갖는 hcv 감염 환자의 치료
CN110075291B (zh) * 2019-02-01 2023-01-06 广州中医药大学(广州中医药研究院) 一种单磷酸类酯A缀合Tn抗肿瘤疫苗及其应用
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
KR20220026538A (ko) 2019-06-05 2022-03-04 에모리 유니버시티 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022008025A1 (en) * 2020-07-05 2022-01-13 Since & Technology Development Fund Authority 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
WO2022234598A1 (en) * 2021-05-06 2022-11-10 Council Of Scientific And Industrial Research A process for the preparation of n4-hydroxycytidine and its derivatives
CN117500494A (zh) 2021-06-17 2024-02-02 阿堤亚制药公司 有利的抗hcv联合疗法
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途
CN113278041B (zh) * 2021-07-16 2021-10-19 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用
CN115960148B (zh) * 2021-08-27 2023-12-12 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
CN115819483A (zh) * 2021-09-17 2023-03-21 南京知和医药科技有限公司 用于治疗癌症的核苷类衍生物及其用途
CN113735928A (zh) * 2021-10-21 2021-12-03 药康众拓(江苏)医药科技有限公司 一种n4-羟基胞苷衍生物及其制备方法和用途
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
TW202400134A (zh) 2022-03-15 2024-01-01 美商羅米醫療公司 用於治療疾病之化合物及方法
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用
CN117285566A (zh) * 2022-06-24 2023-12-26 润佳（苏州）医药科技有限公司 一种膦酸酯类化合物及其医药用途
WO2024123207A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации 5'-о-(3-фенилпропионил)-n4-гидроксицитидин и его применение
WO2024123206A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Способ получения 5',-о-(3-фенилпропионил)-n4-гидроксицитидина
WO2024249234A1 (en) * 2023-05-26 2024-12-05 Altesa BioSciences, Inc. Method of treating hepatitis c virus in patients
WO2025024346A2 (en) * 2023-07-27 2025-01-30 Merck Sharp & Dohme Llc Solid dosage form of a small molecule antiviral and uses thereof

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0656876A (ja) * 1992-06-22 1994-03-01 Eli Lilly & Co 抗ウイルス活性及び抗癌活性を有するヌクレオシド化合物
US5496935A (en) * 1988-08-17 1996-03-05 Max-Delbru/ ck-Centrum 2',3'-dideoxynucleoside pyrimidine compounds and carbocyclic analogs
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
JP2004513083A (ja) * 2000-08-30 2004-04-30 エフ．ホフマン−ラ　ロシュ　アーゲー ヌクレオシド誘導体
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2004065398A2 (en) * 2003-01-15 2004-08-05 Ribapharm Inc. Synthesis and use of 2'-substituted-n6-modified nucleosides
JP2004533406A (ja) * 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
US20050043268A1 (en) * 2001-11-07 2005-02-24 David Loakes Inhibition of viruses
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
CN1626543A (zh) * 2003-12-12 2005-06-15 河南省科学院质量检验与分析测试研究中心 β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
JP2005530759A (ja) * 2002-05-06 2005-10-13 ジェネラブズ テクノロジーズ インコーポレーティッド Ｃ型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体
JP2006505537A (ja) * 2002-09-30 2006-02-16 ジェネラブス テクノロジーズ，インコーポレイテッド Ｃ型肝炎ウイルスの感染を治療するためのヌクレオシド誘導体
US20090105186A1 (en) * 2004-10-21 2009-04-23 Max-Delbrueck-Centrum Fuer Molekulare Medizin Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases
CN102351931A (zh) * 2010-09-07 2012-02-15 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
CN102558263A (zh) * 2010-12-28 2012-07-11 上海瑞广生化科技开发有限公司 去氧氟尿苷类衍生物,其制备方法及其制药用途
JP2012517443A (ja) * 2009-02-06 2012-08-02 アールエフエス ファーマ，エルエルシー 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1081477A (zh) 1992-07-23 1994-02-02 康那香企业股份有限公司 纸纤不织布高分子吸水层的制造方法
JPH07155184A (ja) 1993-12-08 1995-06-20 Ajinomoto Co Inc 発酵法によるｌ−リジンの製造法

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496935A (en) * 1988-08-17 1996-03-05 Max-Delbru/ ck-Centrum 2',3'-dideoxynucleoside pyrimidine compounds and carbocyclic analogs
JPH0656876A (ja) * 1992-06-22 1994-03-01 Eli Lilly & Co 抗ウイルス活性及び抗癌活性を有するヌクレオシド化合物
JP2004513083A (ja) * 2000-08-30 2004-04-30 エフ．ホフマン−ラ　ロシュ　アーゲー ヌクレオシド誘導体
JP2004533406A (ja) * 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
US20050043268A1 (en) * 2001-11-07 2005-02-24 David Loakes Inhibition of viruses
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
JP2005530759A (ja) * 2002-05-06 2005-10-13 ジェネラブズ テクノロジーズ インコーポレーティッド Ｃ型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体
JP2006505537A (ja) * 2002-09-30 2006-02-16 ジェネラブス テクノロジーズ，インコーポレイテッド Ｃ型肝炎ウイルスの感染を治療するためのヌクレオシド誘導体
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2004065398A2 (en) * 2003-01-15 2004-08-05 Ribapharm Inc. Synthesis and use of 2'-substituted-n6-modified nucleosides
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
CN1626543A (zh) * 2003-12-12 2005-06-15 河南省科学院质量检验与分析测试研究中心 β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
US20090105186A1 (en) * 2004-10-21 2009-04-23 Max-Delbrueck-Centrum Fuer Molekulare Medizin Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases
JP2012517443A (ja) * 2009-02-06 2012-08-02 アールエフエス ファーマ，エルエルシー 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ
CN102351931A (zh) * 2010-09-07 2012-02-15 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
CN102558263A (zh) * 2010-12-28 2012-07-11 上海瑞广生化科技开发有限公司 去氧氟尿苷类衍生物,其制备方法及其制药用途

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BANKS, G. R. ET AL., J. MOL. BIOL., vol. 60, JPN6017042082, 1971, pages 425 - 39, ISSN: 0003674470 *
FOX, J. J. ET AL., J. AM. CHEM. SOC., vol. 81, JPN6017042081, 1959, pages 178 - 87, ISSN: 0003674469 *
REGISTRY（STN）[ONLINE], JPN6017042079, 8 June 2008 (2008-06-08), pages 1026541 - 04, ISSN: 0003802362 *
SHI, J. ET AL., BIOORG. MED. CHEM., vol. 13, JPN6017042080, 2005, pages 1641 - 52, ISSN: 0003802363 *
SUZUKI, T. ET AL., NUCLEOIC ACIDS RESEARCH, vol. 34, no. 22, JPN6017042083, 2006, pages 6438 - 49, ISSN: 0003674471 *
TOPAL, M. D. ET AL., NATURE, vol. 298, JPN6017042084, 1982, pages 863 - 5, ISSN: 0003674472 *
ZHANG, H.W. ET AL., BIOORG. MED. CHEM. LETT., vol. 21, no. 22, JPN6017042085, 2011, pages 6788 - 92, ISSN: 0003674473 *
周東智, 有機医薬分子論, vol. 2刷, JPN6017042086, 25 August 2012 (2012-08-25), pages 169 - 71, ISSN: 0003802364 *
周東智, 有機医薬分子論, vol. 2刷, JPN6017042087, 25 August 2012 (2012-08-25), pages 82 - 3, ISSN: 0003674474 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505530A (ja) * 2017-12-07 2021-02-18 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2021042235A (ja) * 2017-12-07 2021-03-18 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP7179372B2 (ja) 2017-12-07 2022-11-29 エモリー ユニバーシティー Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2021523129A (ja) * 2018-05-09 2021-09-02 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. Ｈｃｖを治療するための併用療法
JP7381493B2 (ja) 2018-05-09 2023-11-15 コクリスタル ファーマ，インコーポレイテッド Ｈｃｖを治療するための併用療法
JP2022117326A (ja) * 2021-01-29 2022-08-10 国立大学法人東海国立大学機構 プロドラッグ化合物
JP7774836B2 (ja) 2021-01-29 2025-11-25 国立大学法人東海国立大学機構 プロドラッグ化合物

Also Published As

Publication number Publication date
BR112015009636A8 (pt) 2018-04-17
CN104884462A (zh) 2015-09-02
WO2014070771A1 (en) 2014-05-08
CA2889717A1 (en) 2014-05-08
HK1214270A1 (zh) 2016-07-22
EP2912050A1 (en) 2015-09-02
US9809616B2 (en) 2017-11-07
US20140235566A1 (en) 2014-08-21
BR112015009636A2 (pt) 2017-12-12
MX2015005500A (es) 2016-02-09
RU2015119999A (ru) 2016-12-20
EP2912050A4 (en) 2016-09-28
KR20150090894A (ko) 2015-08-06

Similar Documents

Publication Publication Date Title
US9809616B2 (en) Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
US9173893B2 (en) Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
US8895531B2 (en) 2′-fluoronucleoside phosphonates as antiviral agents
CA2984421C (en) Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US20140212382A1 (en) Purine monophosphate prodrugs for treatment of viral infections
CA2946867C (en) 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US8815829B2 (en) 3′-azido purine nucleotide prodrugs for treatment of viral infections
US20090274686A1 (en) Nucleoside phosphonate derivatives
US20120142627A1 (en) Monophosphate prodrugs of dapd and analogs thereof
HK1195317A (en) Purine monophosphate prodrugs for treatment of viral infections

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20150629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180524